Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prolonged exposure therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    73 result(s) found for: Prolonged exposure therapy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-003891-20 Sponsor Protocol Number: NL17389.091.07 Start Date*: 2007-11-27
    Sponsor Name:GGZ Nijmegen
    Full Title: Een gerandomiseerde placebo gecontroleerde studie naar de toegevoegde waarde van D-cycloserine aan exposure therapie bij patiënten met een poststraumatische stress stoornis
    Medical condition: Posttraumatic stress disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004823-66 Sponsor Protocol Number: ELTCAN1 Start Date*: 2019-04-17
    Sponsor Name:Radboudumc
    Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003482-14 Sponsor Protocol Number: KF5503/24-R331333-PAI-3007 Start Date*: 2007-02-23
    Sponsor Name:Johnson & Johnson Pharamceutical Resarch & Development, L.L.C
    Full Title: A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR* and Oxycodone CR in Subjects with Chronic Pain
    Medical condition: Chronic pain due to knee or hip osteoarthritis or low back pain of benign origin
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NL (Completed) AT (Completed) BE (Completed) GB (Completed) SK (Completed) SI (Prematurely Ended) FR (Completed) CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000073-39 Sponsor Protocol Number: 248.524 Start Date*: 2007-05-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR ...
    Medical condition: Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) CZ (Completed) HU (Completed) AT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000712-30 Sponsor Protocol Number: ABR-71432 Start Date*: 2021-06-07
    Sponsor Name:Radboudumc
    Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation
    Medical condition: Posttraumatic Stress Disorder (PTSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000464-95 Sponsor Protocol Number: IPC-05-2004 Start Date*: 2005-10-14
    Sponsor Name:Inotek Pharmaceuticals Corporation
    Full Title: A phase II randomized, double-blind, placebo-controlled, multi-center study to evaluate tolerability, safety pharmacokinetics and efficacy of intravenous INO-1001 in high-risk subjects undergoing c...
    Medical condition: INO-1001 is being developed for the treatment of high-risk subjects undergoing cardiopulmonary bypass (CPB) for coronary revascularization and/or valve surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000312-36 Sponsor Protocol Number: PTSD-FMS Start Date*: 2021-05-19
    Sponsor Name:Henri Laborit Hospital
    Full Title: Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome
    Medical condition: Post-Traumatic Stress Disorder and fibromyalgia syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10057246 Prolonged post-traumatic stress disorder LLT
    20.0 100000004859 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004591-35 Sponsor Protocol Number: ADVL1211 Start Date*: 2018-12-14
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP)
    Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004230-40 Sponsor Protocol Number: B1871006 Start Date*: 2006-02-17
    Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA
    Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias
    Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005070-11 Sponsor Protocol Number: M13-694 Start Date*: 2015-07-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or I...
    Medical condition: Newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004167-37 Sponsor Protocol Number: ZX008-1502 Start Date*: 2016-05-17
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and You...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NO (Ongoing) DK (Completed) SE (Ongoing) ES (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007170-30 Sponsor Protocol Number: TUD-Psslan-031 Start Date*: 2008-06-03
    Sponsor Name:Technical University of Dresden, faculty of medicine
    Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f...
    Medical condition: Psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-005158-12 Sponsor Protocol Number: NCT-2017-0530 Start Date*: 2019-04-01
    Sponsor Name: Ruprecht-Karls-University Heidelberg Medical Faculty, University Hospital
    Full Title: TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach
    Medical condition: Patients with confirmed diagnosis of Acute Myeloid Leukemia (AML)according to WHO-2016 classification (except acute promyelocytic leukemia) either de novo AML, AML after preceding myelodysplastic o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003525-92 Sponsor Protocol Number: C0743T10 Start Date*: 2006-02-13
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Trial of CNTO 1275, a Fully Human Anti IL 12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic...
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000181-34 Sponsor Protocol Number: OBI-1-301 Start Date*: 2011-06-29
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
    Medical condition: Acquired Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10053761 Acquired hemophilia with anti FVIII, XI, or XIII LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001579-37 Sponsor Protocol Number: 3082B2-311-WW Start Date*: 2006-02-16
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development
    Full Title: An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
    Medical condition: Male subjects with hemophilia A (FVIII:C ≤2% confirmed at screening), previously treated with ≥ 150 exposure days to any Factor VIII product, undergoing elective major surgery that is anticipated t...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SE (Prematurely Ended) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002231-32 Sponsor Protocol Number: PMR-EC-1106 Start Date*: 2009-03-04
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED...
    Medical condition: RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT SIMULECT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) HU (Completed) BE (Completed) CZ (Completed) IE (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) IT (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002804-14 Sponsor Protocol Number: ZX008-1503 Start Date*: 2016-11-08
    Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc
    Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome
    Medical condition: Seizures associated with Dravet syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) DK (Completed) ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000501-23 Sponsor Protocol Number: B7451014 Start Date*: 2018-10-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to seve...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed) BE (Completed) PL (Completed) DE (Completed) LV (Completed) SK (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004013-13 Sponsor Protocol Number: B7451050 Start Date*: 2020-08-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND...
    Medical condition: Moderate to severe atopic dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) SK (Completed) BE (Completed) HU (Completed) CZ (Completed) DK (Prematurely Ended) FI (Completed) BG (Completed) FR (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 10 03:07:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA